^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
Foresight Solid Tumor Recurrence Test

Type:
Laboratory Developed Test
Evidence

News

1year
Foresight Diagnostics & leading cancer center to present solid tumor MRD data at AACR conference (PRNewswire)
"Foresight Diagnostics...announced the presentation of a study in collaboration with a leading cancer center at the upcoming annual meeting of the American Association for Cancer Research (AACR). The poster...describes the results of a study evaluating the performance of the Foresight Solid Tumor Recurrence Test in patients with lung cancer."
Clinical data
|
Foresight Solid Tumor Recurrence Test
over1year
Foresight Diagnostics patent issued for minimal residual disease detection technology (Foresight Diagnostics Press Release)
"Foresight Diagnostics, Inc...announced...that the U.S. Patent and Trademark Office (USPTO) has granted the company patent No. 11,447,833 for the detection of minimal residual disease (MRD) using its personalized phased variant detection platform...This granted patent covers Foresight's PhasED-Seq technology and the workflow behind the Foresight Solid Tumor Recurrence Test, an assay used to detect minimum residual disease (MRD) from the plasma of cancer patients using DNA sequencing."
Patent
|
Foresight Solid Tumor Recurrence Test